Kerri Ford
32 works · 294 citations · h-index 6
Top works
- Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity
- SAT0102 NONINFLAMMATORY PAIN IS A FREQUENT PHENOMENON IN RHEUMATOID ARTHRITIS AND RESPONDS WELL TO TREATMENT WITH SARILUMAB
- POS0606 DISEASE ACTIVITY AND PATIENTS-REPORTED OUTCOMES AFTER SWITCHING BETWEEN IL-6 RECEPTOR INHIBITORS AND JAK INHIBITORS: AN ANALYSIS FROM THE CORRONA REGISTRY
- Case Reports * 1. A Late Presentation of Loeys-Dietz Syndrome: Beware of TGF Receptor Mutations in Benign Joint Hypermobility
- Outcomes and costs of incorporating a multibiomarker disease activity test in the management of patients with rheumatoid arthritis
- Impact of a multi-biomarker disease activity test on rheumatoid arthritis treatment decisions and therapy use
- Disproportionate articular pain is a frequent phenomenon in rheumatoid arthritis and responds to treatment with sarilumab
- The effect of targeted rheumatoid arthritis therapeutics on systemic inflammation and anemia: analysis of data from the CorEvitas RA registry
- Real-World Sarilumab Use and Rule Testing to Predict Treatment Response in Patients with Rheumatoid Arthritis: Findings from the RISE Registry
- Improvement or Worsening of Disease Activity After Switch to Sarilumab in Patients With Rheumatoid Arthritis With a Partial Response to Adalimumab
- Development of an Interactive Tool to Support Shared Decision‐Making in Rheumatoid Arthritis: Treatment Attribute Preference
- Comparative effectiveness of TNF inhibitor vs IL-6 receptor inhibitor as monotherapy or combination therapy with methotrexate in biologic-experienced patients with rheumatoid arthritis: An analysis from the CorEvitas RA Registry
- Clinical Outcomes in Patients with Rheumatoid Arthritis After Switching Between Interleukin-6-Receptor Inhibitors and Janus Kinase Inhibitors: Findings from an Observational Study
- POS0638 DISEASE SEVERITY AND OUTCOMES AMONG PATIENTS WITH RHEUMATOID ARTHRITIS WHO RECEIVE A NEWLY APPROVED BIOLOGIC: REAL-WORLD US EXPERIENCE WITH SARILUMAB FROM THE ACR RISE REGISTRY
- POS1460-HPR PREVALENCE AND MANAGEMENT OF PATIENTS WITH COMORBIDITIES AND FRAILTY IN NEW ONSET POLYMYALGIA RHEUMATICA
- FRI0108 ASSOCIATION BETWEEN CHANGES IN C-REACTIVE PROTEIN AT WEEK 12 AND PATIENT-REPORTED OUTCOMES AT WEEK 24 WITH SARILUMAB THERAPY ACROSS THREE PIVOTAL PHASE 3 STUDIES
- AB1569-HPR CLINICAL AND ECONOMIC BURDEN OF POLYMYALGIA RHEUMATICA IN PATIENTS WITH AN INADEQUATE RESPONSE TO GLUCOCORTICOIDS OR GLUCOCORTICOIDS TAPER IN A REAL-WORLD SETTING
- AB0705 LONG TERM SAFETY OF CONVENTIONAL AND BIOLOGIC IL-6RI IMMUNOMODULATORS AS SECOND-LINE (2L) OR THIRD-LINE (3L) TREATMENT OF POLYMYALGIA RHEUMATICA
- POS1427 EFFECTIVENESS OF INTERLEUKIN-6 RECEPTOR INHIBITORS VERSUS CONVENTIONAL SYNTHETIC IMMUNOMODULATORY THERAPY FOR TREATMENT OF FRAIL PATIENTS WITH POLYMYALGIA RHEUMATICA
- eCDF curves to assess PROMIS-Fatigue meaningful within-person change thresholds in RA clinical trials of Sarilumab